Scholarlink

<p><i>N</i><sup>6</sup>-methyladenosine (m<sup>6</sup>A) represents the most abundant internal RNA modification and a key regulator of gene expression. Although individual m<sup>6</sup>A regulators and sites have been linked to cancer, their transcriptome-wide functional landscape remains undefined. Here we developed an epitranscriptomic screening platform based on targeted m<sup>6</sup>A deposition to identify functional modifications in prostate and lung cancer models. The unbiased screens uncovered 222 m<sup>6</sup>A sites that modulate cell proliferation, predominantly in a cell-type-specific manner. Among them, an m<sup>6</sup>A site within <i>CHD9</i> emerged as a potent tumor-suppressive modification in prostate cancer. Deposition of m<sup>6</sup>A at this site increased CHD9 protein abundance, suppressed cell proliferation and attenuated xenograft growth. Mechanistically, m<sup>6</sup>A at <i>CHD9</i> enhances translation through YTHDF1 and YTHDF3, promoting CHD9–MYBBP1A interaction in the nucleoplasm, sequestrating MYBBP1A from the nucleolus and activating <i>CDKN1A</i> (p21)-associated tumor-suppressive signaling. Collectively, our study establishes a scalable framework for functional mapping of the m<sup>6</sup>A epitranscriptome and uncovers a mechanistic link between <i>CHD9</i> m<sup>6</sup>A modification and tumor suppression, paving the way for systematic exploration of other RNA modifications in cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

METTL3-based epitranscriptomic editing screening identifies functional m6A sites in cancers

  • 期刊论文

  • 发表日期：

    2026年2月6日

查看全文
  • Xin Xu,
  • Yujuan Wang,
  • Helen Zhu,
  • Magnus Lam,
  • Wenqin Luo,
  • Mona Teng,
  • Yin Liu,
  • Wang Yuan Guo,
  • Aastha Aastha,
  • Xi Xu,
  • Sujun Chen,
  • Xinpei Ci,
  • Shiyan Wang,
  • Yong Zeng,
  • Guanghui Zhu,
  • Thomas Kislinger,
  • Mathieu Lupien,
  • Ming-Sound Tsao,
  • Housheng Hansen He

摘要

N6-methyladenosine (m6A) represents the most abundant internal RNA modification and a key regulator of gene expression. Although individual m6A regulators and sites have been linked to cancer, their transcriptome-wide functional landscape remains undefined. Here we developed an epitranscriptomic screening platform based on targeted m6A deposition to identify functional modifications in prostate and lung cancer models. The unbiased screens uncovered 222 m6A sites that modulate cell proliferation, predominantly in a cell-type-specific manner. Among them, an m6A site within CHD9 emerged as a potent tumor-suppressive modification in prostate cancer. Deposition of m6A at this site increased CHD9 protein abundance, suppressed cell proliferation and attenuated xenograft growth. Mechanistically, m6A at CHD9 enhances translation through YTHDF1 and YTHDF3, promoting CHD9–MYBBP1A interaction in the nucleoplasm, sequestrating MYBBP1A from the nucleolus and activating CDKN1A (p21)-associated tumor-suppressive signaling. Collectively, our study establishes a scalable framework for functional mapping of the m6A epitranscriptome and uncovers a mechanistic link between CHD9 m6A modification and tumor suppression, paving the way for systematic exploration of other RNA modifications in cancer.